ZA895325B - Neutralization of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and the fragments derived therefrom - Google Patents

Neutralization of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and the fragments derived therefrom

Info

Publication number
ZA895325B
ZA895325B ZA895325A ZA895325A ZA895325B ZA 895325 B ZA895325 B ZA 895325B ZA 895325 A ZA895325 A ZA 895325A ZA 895325 A ZA895325 A ZA 895325A ZA 895325 B ZA895325 B ZA 895325B
Authority
ZA
South Africa
Prior art keywords
tnf
neutralization
vitro
alpha
monoclonal antibodies
Prior art date
Application number
ZA895325A
Inventor
Achim Moeller
Moeller Achim
Franz Emling
Emling Franz
Manfred Kurfuerst
Kurfuerst Manfred
Thomas Meyer
Meyer Thomas
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA895325B publication Critical patent/ZA895325B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA895325A 1988-07-14 1989-07-13 Neutralization of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and the fragments derived therefrom ZA895325B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3823804A DE3823804A1 (en) 1988-07-14 1988-07-14 NEUTRALIZATION OF THE TOXIC PROPERTIES OF TNF- (ALPHA) IN VITRO AND VIVO BY MONOCLONAL ANTIBODIES AND THE FRAGMENTS DERIVED FROM THEM

Publications (1)

Publication Number Publication Date
ZA895325B true ZA895325B (en) 1991-04-24

Family

ID=6358617

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA895325A ZA895325B (en) 1988-07-14 1989-07-13 Neutralization of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and the fragments derived therefrom

Country Status (6)

Country Link
EP (1) EP0350690A3 (en)
JP (1) JPH02109994A (en)
DE (1) DE3823804A1 (en)
DK (1) DK346789A (en)
FI (1) FI893428A (en)
ZA (1) ZA895325B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE69231828T3 (en) * 1991-03-18 2008-06-19 New York University Specific anti-human tumor necrosis factor monoclonal and chimeric antibodies
US6193969B1 (en) * 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
DE69626829T2 (en) * 1995-08-04 2004-03-18 Lek Farmacevtska Druzba D.D. MONOCLONAL ANTIBODIES AGAINST SOLUBLE TNF-ALPHA RECEPTORS P55 AND P75 AND ALSO AGAINST TNF-ALPHA AND ITS ANALOGS
GB9517538D0 (en) * 1995-08-26 1995-10-25 Therapeutic Antibodies Inc Production and therapeutic combinations, of antibodies
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
CA2508375C (en) 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
RU2010107994A (en) * 2007-08-08 2011-09-20 Эбботт Лэборетриз (Us) COMPOSITIONS AND METHODS OF CRYSTALLIZING ANTIBODIES
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
MA47362A (en) 2017-01-30 2019-12-04 Janssen Biotech Inc ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM
MA47442A (en) 2017-02-07 2019-12-18 Janssen Biotech Inc ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLARTHRITIS
BR112021023295A2 (en) 2019-05-23 2022-02-08 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf-alpha

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3631229A1 (en) * 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
EP0355067A1 (en) * 1988-08-19 1990-02-21 Celltech Limited Pharmaceutical products for anti-neoplastic therapy

Also Published As

Publication number Publication date
EP0350690A2 (en) 1990-01-17
DK346789D0 (en) 1989-07-13
EP0350690A3 (en) 1990-07-04
JPH02109994A (en) 1990-04-23
FI893428A (en) 1990-01-15
DK346789A (en) 1990-01-15
FI893428A0 (en) 1989-07-14
DE3823804A1 (en) 1990-01-18

Similar Documents

Publication Publication Date Title
ZA895325B (en) Neutralization of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and the fragments derived therefrom
EG19493A (en) Novel antibodies reactive with human carcinomas
IL88145A0 (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8910395D0 (en) Human monoclonal antibody and hybridoma producing the same
OA09658A (en) Materials and methods for the treatment of foreign tissue
AU628288B2 (en) Cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
HU9200293D0 (en) Process for the production of monoclonal antibodies and their fragments
AU6036690A (en) Human monoclonal antibodies to hiv-1mn gp 120
EP0438339A3 (en) Process for obtaining articles having the aspect of natural stones and articles obtained
NZ234049A (en) Peptide epitopes of, and antibodies to htlv-1
AU9053991A (en) Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
EP0285511A3 (en) Monoclonal antibodies and their uses
GB9102616D0 (en) Antibodies and their use as drug vectors
IL86960A0 (en) Preparation of human monoclonal antibodies
HK87195A (en) Process for the preparation of sulfated alkanol or alkylphenolox-ethylates with low content of 1,4 dioxane
GB8901832D0 (en) Human monoclonal antibody and its production and use
EP0407586A4 (en) Human monoclonal antibody and process for its preparation
ZA907279B (en) Antibodies and proteins
GB9010190D0 (en) Composition for the treatment of protozoal disease and their use
EP0427942A3 (en) Process for the preparation of s-triazine-sulfenimides and their use
MX9203512A (en) NEUTRALIZATION OF THE IN VITRO AND LIVE TOXIC PROPERTIES OF TNF-ALPHA THROUGH MONOCLONAL ANTIBODIES AND THE FRAGMENTS DERIVED FROM THEM.
AU6964891A (en) Novel monoclonal antibody against human platelets
EP0414921A4 (en) Human monoclonal antibody reactive with pseudomonas aeruginosa, cell which produces the antibody, method of production, and pharmaceutical preparation
EP0466262A3 (en) Process for the preparation of zinc carbocysteinate compositions and their use in hepatopathies
IE891095L (en) Human monoclonal antibodies